Guardion Health Sciences, Inc., together with its subsidiaries, operates as a specialty health sciences company in the United States. It operates in two segments, Medical Foods and Nutraceuticals, and Medical Devices. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. It also provides MapcatSF, a medical device that measures the macular pigment optical density; CSV-1000 device that offers auto-calibrated tests to ensure the correct testing luminance and contrast levels; and CSV-2000, a digital standardized contrast sensitivity testing device, as well as develops, manufactures, and sells equipment and supplies for standardized vision testing under the VectorVision name for use by eye doctors in clinical trials, real-world vision evaluation, and industrial vision testing. In addition, the company develops ImmuneSF, a nutraceutical formulation, as well as a portfolio of nutraceutical products under the NutriGuard brand. Further, it distributes medical foods products through e-commerce in an online store, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in San Diego, California.
IPO Year: 2019
Exchange: NASDAQ
Website: guardionhealth.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/8/2022 | $0.60 | Buy | Maxim Group |
Maxim Group initiated coverage of Guardion Health Sciences with a rating of Buy and set a new price target of $0.60
4 - Guardion Health Sciences, Inc. (0001642375) (Issuer)
3 - Guardion Health Sciences, Inc. (0001642375) (Issuer)
3 - Guardion Health Sciences, Inc. (0001642375) (Issuer)
4 - Guardion Health Sciences, Inc. (0001642375) (Issuer)
4 - Guardion Health Sciences, Inc. (0001642375) (Issuer)
4 - Guardion Health Sciences, Inc. (0001642375) (Issuer)
4 - Guardion Health Sciences, Inc. (0001642375) (Issuer)
4 - Guardion Health Sciences, Inc. (0001642375) (Issuer)
3 - Guardion Health Sciences, Inc. (0001642375) (Issuer)
4 - Guardion Health Sciences, Inc. (0001642375) (Issuer)
8-K - Guardion Health Sciences, Inc. (0001642375) (Filer)
8-K - Guardion Health Sciences, Inc. (0001642375) (Filer)
25 - Guardion Health Sciences, Inc. (0001642375) (Filer)
8-K - Guardion Health Sciences, Inc. (0001642375) (Filer)
8-K - Guardion Health Sciences, Inc. (0001642375) (Filer)
144 - Guardion Health Sciences, Inc. (0001642375) (Subject)
8-K - Guardion Health Sciences, Inc. (0001642375) (Filer)
8-K - Guardion Health Sciences, Inc. (0001642375) (Filer)
10-Q - Guardion Health Sciences, Inc. (0001642375) (Filer)
8-K - Guardion Health Sciences, Inc. (0001642375) (Filer)
HOUSTON, TEXAS, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company") today announced that it has filed a certificate of dissolution with the Secretary of State of the State of Delaware, which became effective upon filing on October 30, 2024 (the "Effective Date"). The filing of the certificate was made pursuant to the terms of the Company's Plan of Liquidation and Dissolution (the "Plan") approved by stockholders at the Company's special meeting of stockholders held on May 31, 2024. As of October 30, 2024, Guardion has closed its stock transfer books, and record holders of shares of the Company's common stock, par value $0.001 per
Plan includes Voluntary Delisting of Common Stock from Nasdaq and Suspension of SEC Reporting Obligations HOUSTON, TEXAS, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company") today announced that it has notified the Nasdaq Stock Market ("Nasdaq") of its intent to delist its common stock, par value $0.001 per share (the "Common Stock"), from the Nasdaq Capital Market. Guardion expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") and Nasdaq relating to the delisting of the Common Stock on or about October 11, 2024 and to suspend trading of its Common Stock on the Nas
HOUSTON, TEXAS, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company") today announced that its Board of Directors declared a cash dividend in an amount equal to $5.00 per share of common stock held by its stockholders of record on September 9, 2024 and a payment date of September 23, 2024. Forward-Looking Statements The matters described herein may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements contain information about our expectations, beliefs, plans or intentions re
Guardion Also Provides an Update to Stockholders of Significant Recent Developments HOUSTON, TEXAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company"), a clinical nutrition company that offers science-based, clinically supported products designed for consumer ocular health, today announced its financial results for the three months and six months ended June 30, 2024, as described below. The Company also provided an update to stockholders of significant recent developments. Recent Developments: Sale of Viactiv® Brand and Business On May 31, 2024, as previously disclosed publicly, the Company completed the sale of all of t
HOUSTON, TEXAS, May 31, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company"), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced that today it closed on its Definitive Agreement to sell its Viactiv business to Doctor's Best Inc. for gross cash consideration of $17,200,000. The Company received net cash proceeds of $16,250,000 at closing, with another $225,000 retained in a third-party escrow account with U.S. Bank, NA, to be released in accordance with the terms of the transac
Adjourns Special Meeting to May 31, 2024 in order to Solicit Additional Proxies in Support of its Plan of Liquidation and Dissolution HOUSTON, TEXAS, May 23, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company"), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced today that its stockholders approved the previously announced sale of its Viactiv business at a special meeting (the "Meeting") held earlier today. Following this approval, the Company then adjourned the Meeting to
Company Estimates the Aggregate Potential Liquidating Distributions to Range from approximately $9.00 to $11.00 per Share if Stockholders Vote to Approve the Sale of the Company's Viactiv Business and the Plan of Liquidation and Dissolution HOUSTON, TEXAS, May 21, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company"), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced today that Mr. Bradley Louis Radoff, who, together with his affiliates, holds approximately 18.92% of the Comp
-- Financial Results for the Three Months Ended March 31, 2024 -- Institutional Shareholder Services Issues Report Recommending that Institutional Stockholders Vote in Favor of All Proposals at the Upcoming Special Meeting of Stockholders on May 23, 2024 Board of Directors Urges Stockholders to Vote to Approve the Sale of the Company's Viactiv Brand and Business and Plan of Liquidation and Dissolution If both proposals are approved, stockholders would receive one or more liquidating cash distributions, which combined are expected to represent a premium over our recent stock price HOUSTON, TEXAS, May 13, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:G
Viactiv® Product Line Generated Net Revenues of Approximately $11.9 Million for the Year Ended December 31, 2023, an Increase of Approximately 12% as Compared to the Year Ended December 31, 2022 HOUSTON, TEXAS, March 29, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company"), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced its financial results for the year ended December 31, 2023. The Company also provided a corporate update to stockholders. Financial highlights for the ye
HOUSTON, TEXAS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company") announced today that it has signed an equity purchase agreement to sell its Activ Nutritional, LLC subsidiary, which owns the Viactiv® brand and business, to Doctor's Best Inc. ("Doctor's Best"), a wholly-owned subsidiary of Kingdomway USA Corp. ("Kingdomway"), for gross cash consideration of $17.2 million, payable in full at closing. The transaction has been approved by the respective Boards of Directors of Guardion and of Doctor's Best, and remains subject to normal and customary closing conditions, including approval of the transaction by the Company's stockholder
Plan includes Voluntary Delisting of Common Stock from Nasdaq and Suspension of SEC Reporting Obligations HOUSTON, TEXAS, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company") today announced that it has notified the Nasdaq Stock Market ("Nasdaq") of its intent to delist its common stock, par value $0.001 per share (the "Common Stock"), from the Nasdaq Capital Market. Guardion expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") and Nasdaq relating to the delisting of the Common Stock on or about October 11, 2024 and to suspend trading of its Common Stock on the Nas
HOUSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company"), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced that Janet ("Jan") Hall has been appointed as the Company's new President and Chief Executive Officer. Ms. Hall is assuming these executive positions from Bret Scholtes, who has served in those positions since January 6, 2021. Mr. Scholtes is resigning effective June 9, 2023, and is also concurrently resigning from the Board of Directors of the Company. Ms.
AgEagle Announces Appointment of Kelly Anderson, CPA to the Board of DirectorsWICHITA, KS / ACCESSWIRE / December 7, 2022 / AgEagle Aerial Systems Inc. (NYSE:UAVS) ("AgEagle" or the "Company"), an industry-leading provider of full stack flight hardware, sensors and software for commercial and government/defense use, today announced the appointment of Kelly Anderson, CPA as a new independent member of AgEagle's Board of Directors, effective today, December 5, 2022. Anderson will also serve as Chairperson of the Audit Committee and as a member of both the Compensation Committee and Nominating and Corporate Governance Committee of the Board, effective December 5, 2022."We are very pleased to we
HOUSTON, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company"), a clinical nutrition and diagnostics company that develops clinically supported nutrition, medical foods, supplements, and medical devices, announced today that Michaela Griggs, a seasoned healthcare executive, has been appointed to its Board of Directors. "We are very excited to welcome Michaela to our Board of Directors. Her marketing acumen and deep experience in both the consumer-driven and healthcare professional-driven markets make her an excellent addition to our already strong Board of Directors," commented Robert N. Weingarten, Guardion's Chairman of the Boar
SAN DIEGO, June 03, 2021 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company"), a clinical nutrition and diagnostics company that develops clinically supported nutrition, supplements, medical foods and medical devices, today announced the appointment of Craig J. Sheehan as its Chief Commercial Officer. Mr. Sheehan joins Guardion following the Company's recent acquisition of Activ Nutritional. Mr. Sheehan was the senior executive responsible for the Viactiv brand as a member of the executive leadership team of Adare Pharmaceuticals for the last four years. Prior to that position, Mr. Sheehan served in key marketing leadership positions at Church & D
SAN DIEGO, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a specialty health sciences company that develops clinically supported nutrition, medical foods and medical devices, with a focus in the ocular health marketplace, today announces the appointment of Bret Scholtes, a veteran of the nutritional products industry for nearly a decade, as its President and Chief Executive Officer, and as a member of the Board of Directors, commencing January 6, 2021. “We are delighted to welcome Bret to Guardion Health Sciences. We believe that his proven business acumen and extensive experience in the nutritional products industry will ser
HOUSTON, TEXAS, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company") today announced that it has filed a certificate of dissolution with the Secretary of State of the State of Delaware, which became effective upon filing on October 30, 2024 (the "Effective Date"). The filing of the certificate was made pursuant to the terms of the Company's Plan of Liquidation and Dissolution (the "Plan") approved by stockholders at the Company's special meeting of stockholders held on May 31, 2024. As of October 30, 2024, Guardion has closed its stock transfer books, and record holders of shares of the Company's common stock, par value $0.001 per
HOUSTON, TEXAS, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company") today announced that its Board of Directors declared a cash dividend in an amount equal to $5.00 per share of common stock held by its stockholders of record on September 9, 2024 and a payment date of September 23, 2024. Forward-Looking Statements The matters described herein may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements contain information about our expectations, beliefs, plans or intentions re
Guardion Also Provides an Update to Stockholders of Significant Recent Developments HOUSTON, TEXAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company"), a clinical nutrition company that offers science-based, clinically supported products designed for consumer ocular health, today announced its financial results for the three months and six months ended June 30, 2024, as described below. The Company also provided an update to stockholders of significant recent developments. Recent Developments: Sale of Viactiv® Brand and Business On May 31, 2024, as previously disclosed publicly, the Company completed the sale of all of t
-- Financial Results for the Three Months Ended March 31, 2024 -- Institutional Shareholder Services Issues Report Recommending that Institutional Stockholders Vote in Favor of All Proposals at the Upcoming Special Meeting of Stockholders on May 23, 2024 Board of Directors Urges Stockholders to Vote to Approve the Sale of the Company's Viactiv Brand and Business and Plan of Liquidation and Dissolution If both proposals are approved, stockholders would receive one or more liquidating cash distributions, which combined are expected to represent a premium over our recent stock price HOUSTON, TEXAS, May 13, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:G
Viactiv® Product Line Generated Net Revenues of Approximately $11.9 Million for the Year Ended December 31, 2023, an Increase of Approximately 12% as Compared to the Year Ended December 31, 2022 HOUSTON, TEXAS, March 29, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company"), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced its financial results for the year ended December 31, 2023. The Company also provided a corporate update to stockholders. Financial highlights for the ye
Viactiv® Generated Net Revenues of Approximately $3.3 Million for the Three Months Ended September 30, 2023, an increase of 27% over the Three Months Ended September 30, 2022 HOUSTON, TEXAS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company"), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced its financial results for the three months and nine months ended September 30, 2023. The Company also provided a corporate update to stockholders. Financial highlights fo
HOUSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company"), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced its financial results for the three months and six months ended June 30, 2023. The Company also provided a corporate update to stockholders. Financial highlights for the three months and six months ended June 30, 2023 include the following (all common share and per share amounts shown below have been adjusted to reflect the 1-for-50 reverse stock split ef
HOUSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company"), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced its financial results for the three months ended March 31, 2023. The Company also provided a corporate update to stockholders. Financial and other highlights for the three months ended March 31, 2023 include the following (all common share and per share amounts shown below have been adjusted to reflect the 1-for-50 reverse stock split effective Janua
HOUSTON, April 17, 2023 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company"), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced its financial results for the year ended December 31, 2022. The Company also provided a corporate update to stockholders. Financial and other highlights for the year ended December 31, 2022 include the following (all common share and per share amounts shown below have been adjusted to reflect the 1-for-50 reverse stock split effective January 6, 2023):
HOUSTON, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. ("Guardion" or the "Company") (NASDAQ:GHSI), a clinical nutrition company that offers a portfolio of science-based, clinically supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 495,000 shares of Series C convertible redeemable preferred stock and 5,000 shares of Series D non-convertible redeemable preferred stock. Each share of Series C and Series D preferred stock has a purchase price of $9.50 per share, reflecting an origin
SC 13G/A - Guardion Health Sciences, Inc. (0001642375) (Subject)
SC 13G/A - Guardion Health Sciences, Inc. (0001642375) (Subject)
SC 13G/A - Guardion Health Sciences, Inc. (0001642375) (Subject)
SC 13G/A - Guardion Health Sciences, Inc. (0001642375) (Subject)
SC 13G - Guardion Health Sciences, Inc. (0001642375) (Subject)
SC 13G/A - Guardion Health Sciences, Inc. (0001642375) (Subject)
SC 13G/A - Guardion Health Sciences, Inc. (0001642375) (Subject)
SC 13G - Guardion Health Sciences, Inc. (0001642375) (Subject)
SC 13G - Guardion Health Sciences, Inc. (0001642375) (Subject)
SC 13G/A - Guardion Health Sciences, Inc. (0001642375) (Subject)